Quality of life as a prognostic marker in pulmonary arterial hypertension
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/38109 http://dx.doi.org/10.1186/s12955-014-0130-3 |
Resumo: | Background: Improvement in quality of life together with better survival are the ultimate goals in the treatment of pulmonary arterial hypertension (PAH) patients. the objective of this study was to evaluate the health-related quality of life (HRQL) of pulmonary arterial hypertension (PAH) patients with the SF-36 generic questionnaire and to identify the prognostic implication of this assessment.Methods: Fifty-four consecutive newly diagnosed PAH patients (WHO classification group I) in a single PAH reference center were included. Patients were evaluated at baseline for clinical and hemodynamic parameters, and they subsequently received first-line therapy with either an endothelin receptor antagonist or a phosphodiesterase-5 inhibitor. After 16 weeks of specific PAH therapy, all patients were re-evaluated using a 6MWT and a SF 36 questionnaire, and then they were followed up for at least 36 months.Results: After treatment, the patients demonstrated an improved 6MWT (414 +/- 124 m vs. 440 +/- 113 m, p = 0.001). Specific PAH therapy also improved the HRQL scores.Patients with a baseline Physical Component Score (PCS) higher than 32 had a better survival rate than those who had a score under 32 (p = 0.04). Similarly, patients with a PCS of at least a 38 after the 16 week therapy period had a better survival rate when compared with those who did not achieve this value (p = 0.016). Unlike the absolute PCS values, the post-treatment PCS variability was unable to predict better survival rates (p = 0.58).Conclusions: Our findings suggest that HRQL is associated with prognosis in PAH. Furthermore, achieving pre-determined PCS scores might represent a specific goal to be reached in treatment-to-target strategies. |
id |
UFSP_1913f56a8c5deb092179a8156380257a |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/38109 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Fernandes, Caio J. C. S.Martins, Barbara C. S.Jardim, Carlos V. P.Ciconelli, Rozana M. [UNIFESP]Morinaga, Luciana K.Breda, Ana PaulaHoette, SusanaSouza, RogerioUniversidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)2016-01-24T14:37:44Z2016-01-24T14:37:44Z2014-08-30Health and Quality of Life Outcomes. London: Biomed Central Ltd, v. 12, 6 p., 2014.1477-7525http://repositorio.unifesp.br/handle/11600/38109http://dx.doi.org/10.1186/s12955-014-0130-3WOS000342017900001.pdf10.1186/s12955-014-0130-3WOS:000342017900001Background: Improvement in quality of life together with better survival are the ultimate goals in the treatment of pulmonary arterial hypertension (PAH) patients. the objective of this study was to evaluate the health-related quality of life (HRQL) of pulmonary arterial hypertension (PAH) patients with the SF-36 generic questionnaire and to identify the prognostic implication of this assessment.Methods: Fifty-four consecutive newly diagnosed PAH patients (WHO classification group I) in a single PAH reference center were included. Patients were evaluated at baseline for clinical and hemodynamic parameters, and they subsequently received first-line therapy with either an endothelin receptor antagonist or a phosphodiesterase-5 inhibitor. After 16 weeks of specific PAH therapy, all patients were re-evaluated using a 6MWT and a SF 36 questionnaire, and then they were followed up for at least 36 months.Results: After treatment, the patients demonstrated an improved 6MWT (414 +/- 124 m vs. 440 +/- 113 m, p = 0.001). Specific PAH therapy also improved the HRQL scores.Patients with a baseline Physical Component Score (PCS) higher than 32 had a better survival rate than those who had a score under 32 (p = 0.04). Similarly, patients with a PCS of at least a 38 after the 16 week therapy period had a better survival rate when compared with those who did not achieve this value (p = 0.016). Unlike the absolute PCS values, the post-treatment PCS variability was unable to predict better survival rates (p = 0.58).Conclusions: Our findings suggest that HRQL is associated with prognosis in PAH. Furthermore, achieving pre-determined PCS scores might represent a specific goal to be reached in treatment-to-target strategies.Univ São Paulo, Sch Med, Pulm Dept, Inst Heart, BR-05403000 São Paulo, BrazilUniversidade Federal de São Paulo, Rheumatol Dept, São Paulo, BrazilUniversidade Federal de São Paulo, Rheumatol Dept, São Paulo, BrazilWeb of Science6engBiomed Central LtdHealth and Quality of Life OutcomesQuality of lifePulmonary arterial hypertensionSurvivalPrognosisTreatmentQuality of life as a prognostic marker in pulmonary arterial hypertensioninfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000342017900001.pdfapplication/pdf627013${dspace.ui.url}/bitstream/11600/38109/1/WOS000342017900001.pdfc6e2f7b1c183a55c6aea284413ce7f11MD51open accessTEXTWOS000342017900001.pdf.txtWOS000342017900001.pdf.txtExtracted texttext/plain30973${dspace.ui.url}/bitstream/11600/38109/2/WOS000342017900001.pdf.txtf34fe0fa5e302b48939c0bfeb311df5bMD52open access11600/381092023-01-12 22:03:34.631open accessoai:repositorio.unifesp.br:11600/38109Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:12:04.892825Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Quality of life as a prognostic marker in pulmonary arterial hypertension |
title |
Quality of life as a prognostic marker in pulmonary arterial hypertension |
spellingShingle |
Quality of life as a prognostic marker in pulmonary arterial hypertension Fernandes, Caio J. C. S. Quality of life Pulmonary arterial hypertension Survival Prognosis Treatment |
title_short |
Quality of life as a prognostic marker in pulmonary arterial hypertension |
title_full |
Quality of life as a prognostic marker in pulmonary arterial hypertension |
title_fullStr |
Quality of life as a prognostic marker in pulmonary arterial hypertension |
title_full_unstemmed |
Quality of life as a prognostic marker in pulmonary arterial hypertension |
title_sort |
Quality of life as a prognostic marker in pulmonary arterial hypertension |
author |
Fernandes, Caio J. C. S. |
author_facet |
Fernandes, Caio J. C. S. Martins, Barbara C. S. Jardim, Carlos V. P. Ciconelli, Rozana M. [UNIFESP] Morinaga, Luciana K. Breda, Ana Paula Hoette, Susana Souza, Rogerio |
author_role |
author |
author2 |
Martins, Barbara C. S. Jardim, Carlos V. P. Ciconelli, Rozana M. [UNIFESP] Morinaga, Luciana K. Breda, Ana Paula Hoette, Susana Souza, Rogerio |
author2_role |
author author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Fernandes, Caio J. C. S. Martins, Barbara C. S. Jardim, Carlos V. P. Ciconelli, Rozana M. [UNIFESP] Morinaga, Luciana K. Breda, Ana Paula Hoette, Susana Souza, Rogerio |
dc.subject.eng.fl_str_mv |
Quality of life Pulmonary arterial hypertension Survival Prognosis Treatment |
topic |
Quality of life Pulmonary arterial hypertension Survival Prognosis Treatment |
description |
Background: Improvement in quality of life together with better survival are the ultimate goals in the treatment of pulmonary arterial hypertension (PAH) patients. the objective of this study was to evaluate the health-related quality of life (HRQL) of pulmonary arterial hypertension (PAH) patients with the SF-36 generic questionnaire and to identify the prognostic implication of this assessment.Methods: Fifty-four consecutive newly diagnosed PAH patients (WHO classification group I) in a single PAH reference center were included. Patients were evaluated at baseline for clinical and hemodynamic parameters, and they subsequently received first-line therapy with either an endothelin receptor antagonist or a phosphodiesterase-5 inhibitor. After 16 weeks of specific PAH therapy, all patients were re-evaluated using a 6MWT and a SF 36 questionnaire, and then they were followed up for at least 36 months.Results: After treatment, the patients demonstrated an improved 6MWT (414 +/- 124 m vs. 440 +/- 113 m, p = 0.001). Specific PAH therapy also improved the HRQL scores.Patients with a baseline Physical Component Score (PCS) higher than 32 had a better survival rate than those who had a score under 32 (p = 0.04). Similarly, patients with a PCS of at least a 38 after the 16 week therapy period had a better survival rate when compared with those who did not achieve this value (p = 0.016). Unlike the absolute PCS values, the post-treatment PCS variability was unable to predict better survival rates (p = 0.58).Conclusions: Our findings suggest that HRQL is associated with prognosis in PAH. Furthermore, achieving pre-determined PCS scores might represent a specific goal to be reached in treatment-to-target strategies. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014-08-30 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:37:44Z |
dc.date.available.fl_str_mv |
2016-01-24T14:37:44Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Health and Quality of Life Outcomes. London: Biomed Central Ltd, v. 12, 6 p., 2014. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/38109 http://dx.doi.org/10.1186/s12955-014-0130-3 |
dc.identifier.issn.none.fl_str_mv |
1477-7525 |
dc.identifier.file.none.fl_str_mv |
WOS000342017900001.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1186/s12955-014-0130-3 |
dc.identifier.wos.none.fl_str_mv |
WOS:000342017900001 |
identifier_str_mv |
Health and Quality of Life Outcomes. London: Biomed Central Ltd, v. 12, 6 p., 2014. 1477-7525 WOS000342017900001.pdf 10.1186/s12955-014-0130-3 WOS:000342017900001 |
url |
http://repositorio.unifesp.br/handle/11600/38109 http://dx.doi.org/10.1186/s12955-014-0130-3 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Health and Quality of Life Outcomes |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
6 |
dc.publisher.none.fl_str_mv |
Biomed Central Ltd |
publisher.none.fl_str_mv |
Biomed Central Ltd |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/38109/1/WOS000342017900001.pdf ${dspace.ui.url}/bitstream/11600/38109/2/WOS000342017900001.pdf.txt |
bitstream.checksum.fl_str_mv |
c6e2f7b1c183a55c6aea284413ce7f11 f34fe0fa5e302b48939c0bfeb311df5b |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460261854707712 |